Significant Developments: Saint Bella Group (02508) has entered into a strategic partnership with L Catterton to jointly develop a cross-sector high-end maternal-infant and lifestyle ecosystem. MICROPORT NEURO (02172) announced that its APOLLO Dream® Rapamycin Target Eluting Stent System has received Breakthrough Device designation from the FDA. TRANSTHERA-B (02617) has completed the first patient dosing in a Phase II clinical trial of tinengotinib combined with fulvestrant for patients with HR+/HER2- recurrent or metastatic breast cancer who have failed prior treatment. Kintor Pharmaceutical-B (09939) reported that its KX-826 Tincture 1.0% met the primary endpoint in the Phase III stage of a pivotal clinical trial for treating androgenetic alopecia in adult Chinese males. Eden Software (01147) subsidiary has formed a strategic collaboration with Superfusion to promote the integration of computing power and enterprise AI application scenarios. 51WORLD (06651) stated that its two platforms, SimOne and Dataverse, have successfully completed deep integration with NVIDIA Omniverse NuRec neural reconstruction technology. Abbisko-B (02256) announced that its FGFR2/3 inhibitor ABSK061 has been granted Orphan Drug Designation by the FDA for the treatment of achondroplasia.
Operating Performance: China Resources Power (00836) released its annual results, with profit attributable to shareholders reaching HK$14.519 billion, a year-on-year increase of 0.9%. China Tower (00788) reported annual results, with profit attributable to shareholders of RMB 11.63 billion, up 8.4% year-on-year. Geely Automobile (00175) announced annual results, with total revenue rising 25% to RMB 345.2 billion, setting a new historical high. Chery Automobile (09973) reported annual results, with profit attributable to shareholders of RMB 19.019 billion, an increase of 34.6% year-on-year. TENCENT (00700) released its full-year results, with profit attributable to shareholders of RMB 224.842 billion, a 16% year-on-year increase, and a final dividend of HK$5.3 per share. Weibo-SW (09898) reported annual results, with net profit attributable to shareholders of US$449 million, up 49.27% year-on-year. Huazhu Group-S (01179) announced annual results, with total revenue of RMB 25.307 billion, an increase of 5.93% year-on-year. BOSS Zhipin-W (02076) reported a net profit of RMB 2.6905 billion for the year, up 71.7% year-on-year. TOT Biopharm-B (01875) released annual results, with revenue of RMB 748 million, highlighting significant achievements in its strategic transition to CDMO. CNOOC Chemical (03983) disclosed its annual results, with profit attributable to owners of approximately RMB 974 million, a decrease of 9.04% year-on-year. AIA Group (01299) announced annual results, with new business value rising 15% to US$5.516 billion.
Comments